Physician

Bruce H Saidman, MD

According to 2025 Medicare claims, Bruce Saidman, MD (NPI: 1053337295) practices medical oncology in the Scranton--Wilkes-Barre, PA market, with the plurality of this provider's patient population coming from Luzerne, PA. This provider's primary affiliated billing organization is MEDICAL ONCOLOGY ASSOCIATES OF WYOMING VALLEY, PC (NPI: 1134120199; TIN: 232170323) and primary practice location at 18704-5535.

Saidman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,004 traditional Medicare patients, billed 427,524 HCPCS/CPT codes, and received $5,542,225 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 1,338 prescription claims across 240 beneficiaries totaling $6,560,104 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 47 claims. Open Payments data shows 38 records totaling $854. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $3,931,430 and ending at $6,560,104. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $14,700 to $10,332.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,168	294,694	$3,807,777
2016	1,153	351,929	$4,871,211
2017	1,107	479,675	$4,851,723
2018	1,185	649,137	$6,737,307
2019	1,181	603,067	$6,448,321
2020	981	425,934	$5,855,882
2021	1,041	419,851	$6,116,109
2022	1,053	442,992	$6,050,425
2023	1,069	531,518	$6,204,935
2024	1,004	427,524	$5,542,225

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	309	1,964	$3,931,430
2016	317	1,971	$4,519,425
2017	317	1,821	$3,987,288
2018	320	2,093	$4,781,217
2019	321	1,894	$4,434,043
2020	297	1,674	$5,506,732
2021	263	1,343	$4,985,282
2022	242	1,201	$3,925,133
2023	244	1,202	$4,518,698
2024	240	1,338	$6,560,104

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	106	613	$82,215
2016	75	686	$62,543
2017	86	780	$37,840
2018	110	972	$42,100
2019	139	725	$40,288
2020	81	502	$33,349
2021	25	105	$7,044
2022	26	52	$2,298
2023	N/R	N/R	N/R
2024	11	47	$2,152

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	663	1,709	$67
80053	Blood test, comprehensive group of blood chemicals	382	1,383	$10
36415	Insertion of needle into vein for collection of blood sample	383	827	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	670	2,677	$8
83615	Lactate dehydrogenase (enzyme) level	266	869	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	42	1,260	$776,514
Brukinsa	Zanubrutinib	41	1,230	$625,791
Calquence	Acalabrutinib Maleate	36	1,080	$532,806
Pomalyst	Pomalidomide	20	560	$452,536
Nubeqa	Darolutamide	29	870	$411,351

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	11	18	$1,513
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	17	$320
J8521	Capecitabine, oral, 500 mg	N	N/R	12	$319

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	38	$854	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Bruce H. Saidman, MD?

Tedicare shows public-source Medicare data for Bruce H. Saidman, MD (NPI 1053337295), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bruce H. Saidman, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Bruce H. Saidman, MD?

Bruce H. Saidman, MD is linked to MEDICAL ONCOLOGY ASSOCIATES OF WYOMING VALLEY, PC (billing NPI 1134120199) in the available physician profile data.

Does Bruce H. Saidman, MD have Open Payments data?

Bruce H. Saidman, MD has 38 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.